Welcome to Our Parkinson's Place

I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please No advertisers, and No Information about Herbal treatments. Please no advertisements.
This is a free site for all.
Thank you.

Monday, May 15, 2017

Normast Add-on Therapy Reduces Motor, Non-motor Symptoms in Parkinson’s Patients, Study Finds

May 15, 2017 06:15 am | Janet Stewart, MSc

Italian researchers found that when used along with standard medication, Normast (ultra-micronized palmitoylethanolamide, or um-PEA) helped lower both motor and non-motor symptoms in patients with advanced Parkinson’s disease (PD), and slowed disease progression and disability.
Parkinson’s patients gradually lose control of movement, with symptoms worsening over time. Current medications slow the disease’s progress, but do not stop it. The study says um-PEA is well-known for its ability to fight inflammation of neurons in the brain and protect them. In Italy, um-PEA  is marketed as a food under the brand name Normast.
In this study, 30 Parkinson’s patients averaging 73 years of age received 1,200 mg a day of Normast for three months, along with Levadopa (L-DOPA) and other Parkinson’s medications in some cases, and then given 600 mg daily for up to a year.
Researchers used the Motor Disease Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) to evaluate motor and non-motor symptoms of Parkinson’s in their patients. The MDS-UPDRS questionnaire covers four sections: nonmotor aspects of daily living experience, motor aspects  of daily living experience, motor examination and motor complications.
After 12 months, non-motor symptoms scores, using the Non-Motor Aspects of Experiences of Daily Living scale, had fallen from 9.7 to 4.5 in patients receiving Normast and Levadopa (L-DOPA). The average score on the Motor Aspects of Experiences of Daily Living scale dropped from 12.7 to 7.6 over the one-year period, while the average total motor complication score dropped from 8.8 to 4.2. Normast caused no side effects.
The researchers said their findings are similar to those from rodent studies.
“Addition of um-PEA to PD patients receiving levadopa therapy elicited a significant and progressive reduction in the total MDS-UPDRS score (parts I, II, III and IV). For each item, the mean score difference between baseline and end of um-PEA treatment showed a significant reduction in most non-motor and motor symptoms. The number of patients with symptoms at basal was reduced after one year of um-PEA treatment,” they reported, concluding that “um-PEA may be an efficacious adjuvant therapy for PD.”

No comments:

Post a Comment